NİLGÜN EROĞLU

Dr. NİLGÜN EROĞLU

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
NENİLGÜN EROĞLU
NİLGÜN EROĞLU
EEErol Erduran
Erol Erduran
GRGokce Pinar Reis
Gokce Pinar Reis
ABAysenur Bahadır
Aysenur Bahadır

15 May 2023 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
NENİLGÜN EROĞLU
NİLGÜN EROĞLU
HSHilal Susam Sen
Hilal Susam Sen
YKYeter Duzenli Kar
Yeter Duzenli Kar
APAyhan Pektas
Ayhan Pektas
IEIbrahim Eker
Ibrahim Eker
Introduction: Propranolol, a nonselective beta-blocker used in the medical treatment of infantile Hemangioma (IH), has been shown to decrease the levels of vascular endothelial growth factor and reduce angiogenesis with its antiproliferative and antiangiogenetic effects. Materials and Methods: It has been reported that the storage, transport, and secretion of vascular endothelial growth factor (VEGF) are associated with platelet volume indices (PVI). We aimed to investigate the effect of propranolol on PVI in IH patients. Propranolol treatment was started on 22 IH patients. Platelets, mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit values in the follow-ups at months 0, 1, and 2 were compared between 22 patients who received treatment and 25 patients who did not. Results: While a statistically significant difference between months 0, 1, and 2 in PDW and MPV values was detected in the treated group, it was not detected in the untreated group. Taking into consideration that VEGF levels were higher at the beginning of the treatment in the pathophysiology of the disease, it was thought that the decrease in VEGF levels by propranolol may have led to a decrease in MPV and PDW levels in the treatment group. Conclusion: Consequently, in IH cases, propranolol response follow-up can be evaluated with PVIs, especially MPV and PDW, and it may facilitate clinicians’ monitoring of the disease after propranolol administration.

7 October 2024 in The Turkish Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
DKDilek Kaçar
Dilek Kaçar
RKRejin Kebudi
Rejin Kebudi
DÖDerya Özyörük
Derya Özyörük
DTDeniz Tuğcu
Deniz Tuğcu
ABAyşenur Bahadır
Ayşenur Bahadır
NYNeşe Yaralı
Neşe Yaralı
Background. Microbiologic confirmation of respiratory tract infections gained importance during the coronavirus disease 2019 (COVID-19) pandemic. This study retrospectively evaluated seasonal distribution, clinical presentation, and complications of respiratory viral infections (RVIs) other than COVID-19 in children with cancer during and after the pandemic lockdown. Methods. Two hundred and sixty-five inpatient and outpatient RVI episodes in 219 pediatric cancer patients confirmed by multiplex reverse transcriptase polymerase chain reaction (RT-PCR) panels from 13 centers were enrolled. Results. Eighty-six (32.5%) of the total 265 episodes occurred in 16 months corresponding to the lockdowns in Türkiye, and the remaining 67.5% in 10 months thereafter. Human rhinovirus/enterovirus (hRE) (48.3%) was the most common agent detected during and after lockdown. Parainfluenza virus (PIV) (23.0%), influenza virus (9.8%), and respiratory syncytial virus (RSV) (9.1%) were the other common agents. The 28.7% of episodes were lower respiratory tract infections (LRTIs), and complications and mortality were higher than upper respiratory tract infections (URTIs) (25.0% vs 5.3%). Bacteremia was identified in 11.5% of culture-drawn episodes. Treatment delay in one-third and death within four weeks after RVI in 4.9% of episodes were observed. Conclusion. During the pandemic, fewer episodes of RVIs occurred during the lockdown period. Respiratory viruses may cause complications, delays in treatment, and even death in children with cancer. Therefore, increased awareness of RVIs and rapid detection of respiratory viruses will benefit the prevention and, in some cases, abrupt supportive and some antiviral treatment of RVI in children with cancer.

12 August 2020 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
NENİLGÜN EROĞLU
NİLGÜN EROĞLU
EEErol Erduran
Erol Erduran
GRGokce Pinar Reis
Gokce Pinar Reis
ABAysenur Bahadır
Aysenur Bahadır

15 March 2021 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
NENİLGÜN EROĞLU
NİLGÜN EROĞLU
TYTamer Yoldas
Tamer Yoldas
BBBurcak Bilgin
Burcak Bilgin
SYSule Yesil
Sule Yesil
AFAli Fettah
Ali Fettah
GSGurses Sahin
Gurses Sahin
Anthracycline chemotherapy is used to treat a variety of cancers. However, late cardiac effects of anthracycline chemotherapy, such as subclinical left ventricular dilatation and/or dysfunction, ha...

1 December 2020 in Journal of Academic Research in Medicine
Verified
Journal Article
Closed access
NENİLGÜN EROĞLU
NİLGÜN EROĞLU
EEErol Erduran
Erol Erduran
ABAyşenur Bahadır
Ayşenur Bahadır
HSHaluk Saruhan
Haluk Saruhan